After Revolution Medicines (RVMD) presented pipeline updates and its 2026 outlook at a competitor conference in the wake of a report that Merck (MRK) is in talks to acquire Revolution for $28B-$32B, Stifel analyst Laura Prendergast said the updates “have us thinking that this speculated $28-32B range might not be enough.” As a company policy, Revolution does not comment on rumors or speculation, notes the analyst, whose target price and Buy rating are currently under review as the firm further evaluates the impact of this Revolution M&A speculation and today’s updates.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines CEO says not commenting on ‘rumors or speculation’
- Revolution Medicines CEO presenting at JPMorgan healthcare conference
- Top 5 Trending Stocks by Unusual Trading Volume, 1/10/26
- Merck in talks to pay about $30B for Revolution Medicines, WSJ says
- STAT’s Adam Feuerstein says Revolution Medicines canceled meeting